title: EGFRandK-RASmutations andERCC1, TUBB3, TYMS, RRM1andEGFRmRNA expression in non-small cell lung cancer: Correlation with clinical response to gefitinib or chemotherapy.
abstract: Personalizing medicines has refined the traditional treatments for non-small-cell lung cancer (NSCLC). In the present study, efforts towards personalizing delivery of care based on the status ofEGFRandK-RASmutations, and mRNA expression levels ofERCC1, TUBB3, TYMS, RRM1andEGFRby choosing appropriate treatments for 52 patients with NSCLC were discussed. Among these 52 NSCLC patients, there were 14 patients treated with gefitinib. Ten patients withEGFRexon 21 point mutations or exon 19 deletions had better treatment outcomes following gefitinib treatment (71.4%). There were 38 patients treated with platinum-based chemotherapy. Docetaxel-platinum based chemotherapy was chosen as the first-line treatment when the patients had low or medianERCC1/TUBB3expression and gemcitabine-platinum based chemotherapy was chosen when the patients had low or medianERCC1/RRM1expression. In total, 26 cases had mRNA expression levels ofERCC1/TUBB3orERCC1/RRM1that could be used to predict the treatment outcomes of chemotherapy (68.4%). The present results indicated that the mutation status ofEGFR, as well as the mRNA expression levels ofERCC1, TUBB3andRRM1, could be used as predictors of the response to gefitinib or chemotherapy.
authors.affiliation: Medical School of Chinese PLA General Hospital, Beijing 100853, P.R. China ; Department of Thoracic-Cardio Surgery, First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China.
authors.forename: Nannan
authors.initials: N
authors.lastname: Guo
authors.affiliation: Department of Thoracic-Cardio Surgery, First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China.
authors.forename: Wen
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Thoracic-Cardio Surgery, First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China.
authors.forename: Baoshi
authors.initials: B
authors.lastname: Zhang
authors.affiliation: Department of Thoracic-Cardio Surgery, First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China.
authors.forename: Yingjie
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Thoracic-Cardio Surgery, First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China.
authors.forename: Jian
authors.initials: J
authors.lastname: Tang
authors.affiliation: Department of Thoracic-Cardio Surgery, First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China.
authors.forename: Shaojun
authors.initials: S
authors.lastname: Li
authors.affiliation: Department of Thoracic-Cardio Surgery, First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China.
authors.forename: Yingnan
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Department of Thoracic-Cardio Surgery, First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China.
authors.forename: Yunlong
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Department of Thoracic-Cardio Surgery, First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China.
authors.forename: Hui
authors.initials: H
authors.lastname: Xia
authors.affiliation: Department of Thoracic-Cardio Surgery, First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China.
authors.forename: Changhai
authors.initials: C
authors.lastname: Yu
keywords: EGFR and K-RAS mutation status; ERCC1; RRM1 and EGFR mRNA expression levels; TUBB3; chemotherapy; gefitinib; non-small-cell lung cancer